Nanobiotix Halts Trading on Euronext Paris Amid Global Share Offering
Event summary
- Nanobiotix requested a temporary trading halt of its ordinary shares on Euronext Paris starting May 21, 2026, at 9:00 a.m. CEST.
- The halt is to facilitate the confirmation of allocations and pricing for its ongoing Global Offering, including a U.S. ADS offering and an International Ordinary Shares and pre-funded warrants offering.
- Trading is expected to resume on May 21, 2026, at approximately 3:30 p.m. Paris time / 9:30 a.m. New York time.
The big picture
Nanobiotix's trading halt underscores the strategic importance of its Global Offering, which aims to bolster its financial position amid the competitive biotechnology landscape. The move reflects broader trends in capital raising among late-stage clinical biotech companies seeking to fund expansive therapeutic pipelines. The success of this offering could influence Nanobiotix's ability to execute its physics-based therapeutic approaches and maintain its position in the oncology and central nervous system disorder markets.
What we're watching
- Offering Execution
- Whether Nanobiotix can successfully complete its Global Offering and the impact of the trading halt on investor confidence.
- Market Reaction
- How the market will react to the resumption of trading and the final pricing of the Global Offering.
- Strategic Use of Proceeds
- The pace at which Nanobiotix will deploy the proceeds from the offering to advance its clinical-stage pipeline.
Related topics